Clinical trials: Coronavirus Infection
COVID-19, Lung Infection
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the potential of opaganib to improve and/or…
- Trial name
- NCT04467840
- Testing
- Opaganib
- Where
- 57 sites in United States, Brazil and 8 more
- Volunteers
- 475 people
- Sponsor
- RedHill Biopharma Limited
SARS-CoV-2, COVID-19
Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay
The purpose of this clinical trial is to demonstrate the clinical performance of the VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay in detecting SARS-CoV-2, Flu A, Flu B and RSV in symptomatic population.
- Conditions
- SARS-CoV-2, COVID-19, RSV, Influenza
- Trial name
- NCT06689423
- Testing
- Credo POCT Device
- Where
- Taiwan
- Volunteers
- 1,268 people
- Sponsor
- Credo Diagnostics Biomedical Pte. Ltd.
COVID-19 Pandemic
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2…
- Trial name
- COVID-19 (NCT05125874)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19
Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine
This was a randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety and immunogenicity of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen)…
- Trial name
- NCT05175625
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Cinnagen
Covid19
Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products
SARS COVID 2 has caused a pandemic of proportions unparalleled in the past 100 years. The virus has an uncanny ability for transmission and as such has been difficult to control.
- Trial name
- NCT04864925
- Testing
- Colgate Total Clean Mint, Tom's Botanically Bright Peppermint
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Colgate Palmolive
Covid-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory COVID-19 patients.
- Trial name
- NCT04348474
- Testing
- Hydroxychloroquine Sulfate, Azithromycin Tablets
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- Azidus Brasil
Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903) with supplemental oxygenation.
- Trial name
- NCT05091723
- Testing
- Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Long COVID, Post-COVID Syndrome
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
- Conditions
- Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
- Trial name
- NCT05682560
- Testing
- REGENECYTE
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- StemCyte, Inc.
Covid19, SARS-COV-2 Infection
A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
- Trial name
- NCT04721535
- Testing
- DWJ1248
- Where
- South Korea
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Influenza Infection, SAD-RV Infection and COVID-19
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
- Trial name
- STOP-Flu (NCT04298060)
- Testing
- DAS181
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Ansun Biopharma, Inc.
Covid19
Study of Codivir in Patients With COVID-19
This is an open-label study to evaluate the safety and preliminary efficacy of Codivir in 12 mild or moderate COVID-19 patients and onset of symptoms within 72h prior to their inclusion.
- Trial name
- Codivir (NCT04930861)
- Testing
- Covidir injections, One Step Test, IgM and IgG dosage
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Code Pharma
COVID-19, SARS-CoV-2 Infection
A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects
Trial to evaluate the safety and immunogenicity of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 (Variant of concern [VOC] strain B.1.351) in BNT162-01 trial participants, or two boosting doses of Comirnaty in…
- Trial name
- NCT04949490
- Testing
- BNT162b2s01, BNT162b2
- Where
- 4 sites in Germany
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Healthy
Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
ZYIL1 is a novel oral selective NLRP3 inflammasome inhibitor which prevents NLRP3-induced ASC oligomerization, thus inhibiting NLRP3 inflammasome pathway.
- Trial name
- NCT04731324
- Testing
- ZYIL1 capsule
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
This study is a randomized, double-blind, placebo-controlled I/II clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation in adults 18…
- Trial name
- NCT04840992
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID-19, Coronavirus Infection
Piclidenoson for Treatment of COVID-19
Patients with documented moderate COVID-19 infection will be randomized 1:1 to receive piclidenoson 2 mg Q12H orally with standard supportive care (SSC - intervention arm) or placebo orally with SSC (control arm) for up to 28…
- Trial name
- NCT04333472
- Testing
- Piclidenoson
- Where
- 6 sites in Bulgaria, Israel and 1 more
- Volunteers
- 6 people
- Sponsor
- Can-Fite BioPharma
SARS-CoV-2 Infection, Anti-SARS-CoV-2 Infection
Registry of Sustained Immunity to COVID-19 Among ESKD Patients
This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center.
- Trial name
- RePAiR (NCT04495764)
- Where
- 12 sites in United States
- Volunteers
- 2,315 people
- Sponsor
- Davita Clinical Research
COVID-19 Respiratory Infection, SARS-CoV2 Infection
Echinaforce COVID-19 Shedding Study
Respiratory viruses pose a permanent threat to humans and society as demonstrated by the current Covid-19 pandemic. Novel drugs and vaccines provide a means for controlling illness.
- Trial name
- NCT04999098
- Testing
- Echinaforce Forte tablets, Echinaforce Chewable tablets, Echinaforce tincture
- Where
- Bulgaria
- Volunteers
- 40 people
- Sponsor
- A. Vogel AG
Covid19
COVID-19 International Drug Pregnancy Registry
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild…
- Trial name
- COVID-PR (NCT05013632)
- Testing
- Antiviral Agents, Monoclonal antibody
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Pregistry
COVID-19
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
The main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at…
- Trial name
- LIBERTY (NCT07655180)
- Testing
- COVID-19 mRNA vaccine, VYD2311
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Invivyd, Inc.
Coronavirus Disease 2019 (COVID-19)
CSL324 in COVID-19
This is a phase 2, prospective, multicenter, randomized, double blind, placebo controlled, parallel group study to evaluate the safety and efficacy of intravenous (IV) administration of CSL324, administered in combination with…
- Trial name
- NCT04519424
- Testing
- CSL324
- Sponsor
- CSL Behring
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.